Medicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.
Medicare will restrict coverage of the controversial and costly Alzheimer's drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.
The final decision, which follows a proposed policy released in January, will have far-reaching consequences for millions of Alzheimer's patients and tens of millions of Medicare enrollees. It's the latest step in the drug's contentious path to market. It is expected to restrict the number of people who can receive the medication.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Medicare limits payments for new Alzheimer’s drug to clinical trialsThe federal government affirmed its plan to limit coverage for a costly new medication for Alzheimer’s disease, restricting it to Medicare patients enrolled in clinical trials.
Read more »
Medicare Considers Cutting Premiums After Limiting Alzheimer’s Drug CoverageMedicare said Thursday it’s considering a cut in enrollee premiums after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs.
Read more »
New generation of cancer-preventing vaccines could wipe out tumors before they formCancer-preventing vaccines are now being tested in healthy people at high risk for disease—and early trials are yielding glimmers of promise. LongReads
Read more »
UCSD joins clinical trial to evaluate need for additional COVID-19 boostersUC San Diego joined a Phase II clinical trial to evaluate additional COVID-19 booster shots to see if different vaccine regimens can broaden immune responses in adults, it was announced Wednesday.
Read more »
San Diego will be part of national clinical trial on COVID-19 vaccinesEffort will be led locally by UC San Diego with almost half of participants 65 or older
Read more »